Catalent lands $4.1B debt deal to expand biologics and oral drug capacity
What's the deal? CatalentDealroom has a profile for this one. Try Dealroom →, one of the world's largest contract development and manufacturing organisations (CDMO), has completed a $4.1 billion debt refinancing to free up capital for scaling manufacturing capacity. The deal, announced in late August, includes a seven-year Term Loan B facility and a $600 million revolving credit facility, replacing its existing Term Loan B.
Why now? Catalent says it is seeing strong customer demand across biologics, advanced drug delivery, and peptide-based therapies, including GLP-1s. Chief financial officer Matti Masanovich said the company is also expanding US capacity to capture an "onshoring U.S. tailwind."
By the numbers: The refinancing is expected to cut annual interest expense by roughly $100 million and lower Catalent's blended cost of debt. The new revolving credit facility is backed by a syndicate of 10 global banks, leaving Catalent with about $1.1 billion in available liquidity.
What's the endgame? Catalent is directing investment into its Zydis orally disintegrating tablet platform and larger-scale bioreactor capacity at its Madison site. It has also launched Qai, an enterprise AI tool built to speed up root cause analysis for quality processes such as deviations and complaints.
Zoom out: The refinancing comes nearly two years after Novo HoldingsDealroom has a profile for this one. Try Dealroom → completed its $16.5 billion acquisition of Catalent. Novo Holdings said soon after that it planned to double Catalent's size over five years.
The signal: At $4.1 billion, this ranks among the largest debt rounds ever recorded in US healthcare — above the 99th percentile of all such deals. It underscores how heavily capital is flowing into contract manufacturing as onshoring and GLP-1 demand reshape the sector.
Image credit: ITB495
